BOULDER, Colo.--(BUSINESS WIRE)--Apr. 30, 2012--
Array BioPharma Inc. (NASDAQ: ARRY) announced that it has elected Liam
Ratcliffe, M.D., Ph.D., to its Board of Directors as an independent
director. Dr. Ratcliffe has extensive background in drug development and
translational medicine, including a 12-year tenure at Pfizer.
Liam Ratcliffe, M.D., Ph.D., Independent Director, Array BioPharma Board of Directors (Photo: Business Wire)
“We are excited to announce Liam’s addition to the Array Board of
Directors,” said Kyle Lefkoff, Chairman of Array BioPharma. “Liam brings
to Array his world-class experience in the clinical development of our
pain and inflammation portfolio.”
Dr. Ratcliffe commented, “This is an important time for Array and I’m
delighted to be part of the team. I look forward to working with Array’s
new CEO, Ron Squarer, who brings his unique outlook and perspective.”
Dr. Ratcliffe continued, “I’m honored to join the Array Board as an
independent director, and I look forward to fulfilling a role in which I
can reflect the broad interests of Array’s diverse shareholder base.”
Dr. Ratcliffe is a General Partner at New Leaf Venture Partners and
joined New Leaf in September 2008. Prior to joining New Leaf, Dr.
Ratcliffe served as Senior Vice President and Development Head for
Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and
Development. Additional positions at Pfizer included Vice President of
Exploratory Development for the Mid West region, and Head of
Experimental Medicine at Pfizer's Sandwich, UK Laboratories.
Dr. Ratcliffe received his M.D. and Ph.D. degrees in immunology from the
University of Cape Town and his MBA degree from the University of
Michigan. He completed his internal medicine training and fellowship in
Immunology at Groote Schuur Hospital and additional teaching hospitals
in Cape Town, South Africa.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more information on
Array, please go to www.arraybiopharma.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50256857&lang=en
Source: Array BioPharma Inc.
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
